ISSN: 1859 - 2872
The efficacy of irinotecan monotherapy as second-line treatment in patients with advanced gastric cancer
Main Article Content
Keywords
Abstract
Objective: To evaluate the efficacy of irinotecan monotherapy as second - line treatment in patients with advanced gastric cancer. Subject and method: Descriptive, retrospective, longitudinal case study of 43 patients with advanced gastric cancer refactory to or progressive after first-line chemotherapy, treatmented with irinotecan monotherapy as second-line treament from 01/2019 to 4/2024 at Vietnam’s National Cancer Hospital. Result: The mean age was 62.3 ± 11.7 (36-81); female/male ratio was 1/1.15. The overall response rate (ORR) was 18.6%, the DCR was 55.8%. The median progression-free survival (PFS) was 3.0 months; the median overal survival (OS) was 6.2 months. Conclusion: In patients with advanced gastric cancer, irinotecan monotherapy is a resasonable second-line treatment option.
Article Details
References
2. Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15): 2306-2314.
3. Casaretto L, Sousa PLR, Mari JJ (2006) Chemotherapy versus support cancer treatment in advanced gastric cancer: A meta-analysis. Braz J Med Biol Res 39(4): 431-440.
4. Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31(35): 4438-4444.
5. Eisenhauer EA, Therasse P, Bogaerts J et al (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 45(2): 228-247.
6. Cho YH, Yoon SY, Kim SN (2017) Irinotecan monotherapy versus irinotecan-based combination as second-line chemotherapy in advanced gastric cancer: A meta-analysis. Cancer Res Treat 49(1): 255-262.
7. Lee KW, Maeng CH, Kim TY et al (2019) A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist 24(1): 18-24.
8. Ochenduszko S, Puskulluoglu M, Konopka K et al (2017) Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: A single-center observational study. Ther Adv Med Oncol 9(4) 223-233.
Article Sidebar
